News & Updates

New drug applications approved by US FDA as of 1-15 December 2024 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

In patients with cancer cachexia and elevated levels of growth differentiation factor-15 (GDF-15), GDF-15 inhibition with ponsegromab led to a significant increase in body weight and overall activity level and reduction in cachexia symptoms, a phase II study suggests.

Greater body height appears to be associated with increased breast cancer risk among young women in Korea, as suggested in a study.

Use of nanoparticle-directed focal laser ablation results in the successful treatment of several patients with localized  (PCa), as confirmed by negative magnetic resonance (MR)/ultrasound (US) fusion biopsy of the treated lesion and a systematic biopsy.

Dual inhibition of EZH1/2 with valemetostat appears to induce responses in patients with relapsed or refractory peripheral T-cell lymphoma while having a manageable safety profile, according to the results of a single-arm phase II trial.